Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer

Schmidt, Marcus; Petry, Ilka; Böhm, Daniel; Lebrecht, Antje; Törne, Christian von; Gebhard, Susanne; Gerhold‐Ay, Aslihan; Cotarelo, Cristina; Battista, Marco Johannes; Schormann, Wiebke; Freis, Evgenia; Selinski, Silvia; Ickstadt, Katja; Rahnenführer, Jörg; Sebastian, Martin; Schüler, Martin; Koelbl, Heinz; Gehrmann, Mathias; Hengstler, Jan G.

doi:10.1007/s10549-010-0856-5

Cited by 26 publications

(19 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some of the established gene expression signatures have been included as part of the clinical routine. Most of these predictive classification algorithms predominantly rely on ERα-regulated genes and/or on genes involved in proliferation 6 – 11 …”

Section: Breast Cancer Prognosis and The Relevance Biomarkersmentioning

confidence: 99%

Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors

Schmidt¹,

Micke

Gehrmann

et al. 2012

OncoImmunology

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Breast Cancer Prognosis and The Relevance Biomarkersmentioning

confidence: 99%

Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors

Schmidt¹,

Micke

Gehrmann

et al. 2012

OncoImmunology

Self Cite

View full text Add to dashboard Cite

show abstract

“…EpCAM was reported to be exclusively present in epithelial tissues and is highly expressed across a large number of epithelial cancers (2)(3)(4)(5)(6)(7)(8)(9)(10)(11). Particular interest has been focused on EpCAM expression as a poor prognostic biomarker across a large number of carcinomas (2,(4)(5)(6)(8)(9)(10)(12)(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Epithelial cell adhesion molecule is expressed in a subset of sarcomas and correlates to the degree of cytological atypia in leiomyosarcomas

Ward

Amaya

Verma

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Epithelial cell adhesion molecule (EpCAM) is a protein involved in cell-to-cell attachment and is considered to be strictly expressed in epithelial tissues and epithelial-derived tumors. Furthermore, EpCAM has been shown to be a negative prognostic marker for several carcinomas. In this study, we performed a genomic meta-analysis of gene expression profiles housed in the Cancer Cell Line Encyclopedia to demonstrate that EpCAM mRNA is expressed at low to moderate levels in certain sarcoma cell lines. We utilized immunohistochemical staining to confirm that the EpCAM protein is expressed in a subset of angiosarcomas and leiomyosarcomas and in all the investigated osteosarcomas. Finally, we conducted a statistical analysis of clinical data to demonstrate that EpCAM protein expression is significantly and directly correlated with the degree of cytological atypia in leiomyosarcomas. In conclusion, this data suggests that, contrary to conventional beliefs, EpCAM is expressed in a subset of sarcomas and is a negative prognostic marker for leiomyosarcomas.

show abstract

“…This effect was particularly strong in the subgroup of triple-negative breast cancer, making EpCAM an attractive therapeutic target in this patient population. 14,15 EpCAM has a direct impact on cell cycle and proliferation, and the ability to upregulate the proto-oncogene, c-myc, and cyclin A/E rapidly. Furthermore, EpCAM weakens cadherinmediated cell adhesion, and thereby modulates proliferation, differentiation, and tissue maintenance.…”

Section: Introductionmentioning

confidence: 99%

Review of catumaxomab in the treatment of malignant ascites

Sebastian¹

2010

CMAR

Self Cite

View full text Add to dashboard Cite

Malignant ascites is frequently found with various solid tumors, and no established treatment options exist, apart from symptomatic paracentesis. Catumaxomab, a trifunctional bispecific monoclonal antibody, has two binding specificities directed to epithelial cell adhesion molecule (EpCAM) and the T cell antigen CD3. With its Fc-fragment, catumaxomab additionally binds accessory cells, including dendritic cells, macrophages, and natural killer cells. The trifunctional approach thus leads to a major histocompatibility complex-unrestricted but specific killing of epithelial tumor cells without need for preactivation or external costimulation. Because EpCAM is expressed in most solid tumors, but not in tissue of mesothelial origin, intraperitoneal treatment with catumaxomab is tumor-specific. Intraperitoneal treatment with catumaxomab resulted in a significant prolongation of puncture-free survival in patients with malignant ascites due to epithelial cancer. Catumaxomab has been approved in Europe for the intraperitoneal treatment of malignant ascites in patients with EpCAM-positive epithelial tumors where standard therapy is not available or no longer feasible.

show abstract

Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer

Abstract: Christian Törne, et al.. Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer.

Cited by 26 publications

References 29 publications

Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors

Immunoglobulin kappa chain as an immunologic biomarker of prognosis and chemotherapy response in solid tumors

Epithelial cell adhesion molecule is expressed in a subset of sarcomas and correlates to the degree of cytological atypia in leiomyosarcomas

Review of catumaxomab in the treatment of malignant ascites

Contact Info

Product

Resources

About